San Diego, California — September 3, 2026 — Leads & Copy — Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQB: TTIPF), a clinical-stage biotechnology company focused on developing sulfur-based therapeutics for rare diseases, has engaged Brisco Capital Partners Corp. to provide investor relations services. Brisco will support Thiogenesis in enhancing its communications with shareholders, investors, and the broader investment community, aiming to boost awareness of the company and its development programs.
Brisco, an investor relations firm based in Calgary, Alberta, offers services including business development, road shows, corporate communications, and tradeshow advisory to a variety of public companies. Brisco currently holds no securities in Thiogenesis.
The agreement, effective September 1, 2026, stipulates a monthly fee of $6,000 plus applicable taxes for Brisco. Additionally, Brisco will be granted 100,000 stock options, exercisable at $0.50 per share for a term of 36 months, with vesting occurring quarterly over one year. Both the agreement and the option grant are contingent on acceptance by the TSX Venture Exchange.
In a separate matter, Thiogenesis plans to amend its omnibus equity incentive plan. The proposed amendment will increase the number of common shares reserved for issuance under the plan from 9,099,095 to 13,995,931. The plan operates as a fixed 20% security-based compensation plan, allowing for the grant of stock options, restricted share units, and deferred share units. Currently, 5,125,000 awards are outstanding, leaving 3,424,095 awards available for future grants.
The company’s board of directors has determined that the existing reserve is insufficient to meet anticipated incentive compensation needs. The amendment aims to restore the plan reserve to 20% of the company’s current issued and outstanding share capital. This amendment requires acceptance by the TSXV and a disinterested shareholder approval at Thiogenesis’s annual and special meeting of shareholders, scheduled for September 8, 2026.
Thiogenesis Therapeutics Corp., headquartered in San Diego, California, is a clinical-stage biotechnology company dedicated to developing sulfur-based therapeutics for rare diseases. The company’s lead candidate, TTI-0102, is under development for nephropathic cystinosis and primary mitochondrial diseases, including conditions within the Leigh syndrome spectrum. Thiogenesis is progressing TTI-0102 through clinical development with the objective of addressing significant unmet medical needs in rare genetic disorders.
Source: Thiogenesis Therapeutics, Corp.
